Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

NCT06004661 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: AAA617
DRUG: 68Ga-PSMA-11

Sponsor

Novartis Pharmaceuticals